Ledraxen

Enoxaparin Sodium, the active ingredient in Ledraxen, is a low molecular weight heparin presented as an injectable solution for subcutaneous, intravenous, or haemodialysis use. It is employed to prevent and treat thromboembolic disorders in adult patients.

GNH USA supplies Ledraxen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Enoxaparin Sodium is used in the anticoagulation pathway to manage thrombotic conditions.

- Deep vein thrombosis prophylaxis: reduces the risk of clot formation after surgery or immobilisation. - Treatment of established deep vein thrombosis: helps dissolve existing clots and prevents extension. - Pulmonary embolism therapy: limits clot propagation and supports recovery. - Surgical thromboprophylaxis: prevents peri‑operative venous thromboembolism in orthopaedic and abdominal procedures. - Haemodialysis circuit anticoagulation: maintains circuit patency during dialysis sessions.

Common Side Effects: - Injection site erythema or pain. - Minor bleeding such as gum or nasal bleeding. - Bruising at the injection site. - Elevated liver transaminases. - Nausea or mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hemorrhage, including intracranial or gastrointestinal bleeding. - Heparin‑induced thrombocytopenia (HIT). - Allergic reactions ranging from rash to anaphylaxis. - Spinal or epidural hematoma after neuraxial procedures. - Acute renal impairment in susceptible patients.

Enoxaparin Sodium requires careful monitoring in several clinical situations.

- Renal impairment: dose adjustment may be necessary. - History of bleeding: assess risk and monitor closely. - Concurrent anticoagulants or antiplatelet agents: increased bleeding risk. - Pregnancy: use only when benefit outweighs potential fetal risk. - Upcoming surgery or invasive procedures: discontinue according to clinical guidelines. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Enoxaparin Sodium can interact with several medication classes, influencing bleeding risk.

Major Interactions (Avoid): - Other anticoagulants (e.g., warfarin, direct oral anticoagulants). - Thrombolytic agents (e.g., alteplase). - Non‑steroidal anti‑inflammatory drugs (NSAIDs). - Antiplatelet drugs (e.g., clopidogrel, high‑dose aspirin).

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic agents. - Corticosteroids, which may potentiate bleeding. - Drugs affecting renal clearance, requiring dose reassessment.